ACIU
AC Immune SA
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 03-20-2019 | 11-13-2018 | 08-08-2018 | 05-02-2018 | 03-20-2018 | 11-13-2017 | 08-09-2017 | 05-11-2017 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actual EPS | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.22 | -0.19 | -0.2 | -0.2 | 0.06 | -0.16 | -0.22 | -0.17 |
| Consensus EPS | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | -0.27 | -0.23 | -0.23 | -0.2 | -0.07 | -0.17 | |
| Estimated EPS | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | -0.27 | -0.23 | -0.23 | -0.2 | -0.07 | -0.17 | |
| Number of Estimates | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 2 | 2 | 2 | 2 | 1 | 2 | |
| EPS Surprise | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | -$0.77 | $0.08 | $0.03 | $0.03 | $0.04 | -$0.15 |
Stats
Summary
AC Immune SA is a clinical stage biopharmaceutical company. It discovers, designs and develops novel, proprietary medicines for treatment of neurodegenerative diseases with the help of proprietary platforms.
Market Cap: 770 Million
Primary Exchange: NASDAQ Global Market
Website: http://www.acimmune.com
Shares Outstanding: 56.9 Million
Float: 56.9 Million
Dividend: 0.0 (0.0%)
Beta: 1.70028
Sector: Healthcare
Industry: Biotechnology
Short Interest (Jan 12, 2018): 1.76 Million
Ethical Flags
Longest drawdown: 679 trading days
From: 2016-09-28 To: 2019-06-12
Lowest Point:
AC Immune - Light In The End Of Tunnel?
via: SeekingAlpha at 2019-06-06 06:30:43:000
Alzheimer's Disease Alzheimer's disease is a devastating neuro-degenerative disease, one of the common forms of dementia. About 80 percent of dementia cases are caused by Alzheimers disease. Named after the German psychiatrist Alois Alzheimer, the disease is currently diagnose… read more...
AC Immune - Light In The End Of Tunnel?
via: SeekingAlpha at 2019-06-06 06:30:43:000
Alzheimer's Disease Alzheimer's disease is a devastating neuro-degenerative disease, one of the common forms of dementia. About 80 percent of dementia cases are caused by Alzheimers disease. Named after the German psychiatrist Alois Alzheimer, the disease is currently diagnose… read more...
AC Immune - Light In The End Of Tunnel?
via: SeekingAlpha at 2019-06-06 06:30:43:000
Alzheimer's Disease Alzheimer's disease is a devastating neuro-degenerative disease, one of the common forms of dementia. About 80 percent of dementia cases are caused by Alzheimers disease. Named after the German psychiatrist Alois Alzheimer, the disease is currently diagnose… read more...
AC Immune reports Q1 results
via: SeekingAlpha at 2019-05-15 03:10:15:000
AC Immune (NASDAQ: ACIU ): Q1 Non-GAAP EPS of CHF0.85; GAAP EPS of CHF0.91. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q1 results
via: SeekingAlpha at 2019-05-15 03:10:15:000
AC Immune (NASDAQ: ACIU ): Q1 Non-GAAP EPS of CHF0.85; GAAP EPS of CHF0.91. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q1 results
via: SeekingAlpha at 2019-05-15 03:10:15:000
AC Immune (NASDAQ: ACIU ): Q1 Non-GAAP EPS of CHF0.85; GAAP EPS of CHF0.91. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune +3% on new data on alpha-synuclein PET tracer
via: SeekingAlpha at 2019-03-29 03:51:47:000
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression… read more...
AC Immune +3% on new data on alpha-synuclein PET tracer
via: SeekingAlpha at 2019-03-29 03:51:47:000
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression… read more...
AC Immune +3% on new data on alpha-synuclein PET tracer
via: SeekingAlpha at 2019-03-29 03:51:47:000
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression… read more...
AC Immune +3% on new data on alpha-synuclein PET tracer
via: SeekingAlpha at 2019-03-29 03:51:47:000
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression… read more...
AC Immune +3% on new data on alpha-synuclein PET tracer
via: SeekingAlpha at 2019-03-29 03:51:47:000
AC Immune SA (NASDAQ: ACIU ) presents new data on its positron-emission tomography (PET) tracer, which demonstrated a high-affinity binding to human Parkinsons disease-brain derived alpha-synuclein (a-syn),potentially capable of accurately detecting and monitoring progression… read more...
In The Wake Of Biogen's Alzheimer's Failure, Who Do We Turn Our Attention To Now?
via: SeekingAlpha at 2019-03-25 10:26:48:000
Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last we… read more...
In The Wake Of Biogen's Alzheimer's Failure, Who Do We Turn Our Attention To Now?
via: SeekingAlpha at 2019-03-25 10:26:48:000
Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last we… read more...
In The Wake Of Biogen's Alzheimer's Failure, Who Do We Turn Our Attention To Now?
via: SeekingAlpha at 2019-03-25 10:26:48:000
Editor's note: Seeking Alpha is proud to welcome Nicholas Pugliese as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more Last we… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-03-22 08:41:38:000
Gainers: Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-03-22 08:41:38:000
Gainers: Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im… read more...
Microcaps dominate midday movers
via: SeekingAlpha at 2019-03-22 08:41:38:000
Gainers: Seelos Therapeutics (NASDAQ: SEEL ) +40% . Hibbett Sports (NASDAQ: HIBB ) +23% . Bio-Path Holdings (NASDAQ: BPTH ) +18% . Immutep (NASDAQ: IMMP ) +17% . CounterPath (NASDAQ: CPAH ) +12% . Destination Maternity (NASDAQ: DEST ) +11% . Netshoes (NYSE: NETS ) +11% . AC Im… read more...
AC Immune reports FY results
via: SeekingAlpha at 2019-03-21 03:12:52:000
AC Immune (NASDAQ: ACIU ): FY Non-GAAP EPS of -CHF0.76; GAAP EPS of -CHD0.82. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
FB, GE, VLO among premarket gainers
via: SeekingAlpha at 2019-01-31 09:19:45:000
Fortress Biotech (NASDAQ: FBIO ) +56% on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more … read more...
FB, GE, VLO among premarket gainers
via: SeekingAlpha at 2019-01-31 09:19:45:000
Fortress Biotech (NASDAQ: FBIO ) +56% on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more … read more...
FB, GE, VLO among premarket gainers
via: SeekingAlpha at 2019-01-31 09:19:45:000
Fortress Biotech (NASDAQ: FBIO ) +56% on Caelum deal with Alexion. More news on: Fortress Biotech, Inc., Prana Biotechnology Ltd, VistaGen Therapeutics, Inc., Stocks on the move, , Read more … read more...
Another Alzheimer's Antibody Fails. There Will Be More
via: SeekingAlpha at 2019-01-31 02:21:58:000
To what should be absolutely no human being's surprise, another amyloid-antibody trial has failed. Roche ([[RHHBY]]) announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. The company is still going on with… read more...
Another Alzheimer's Antibody Fails. There Will Be More
via: SeekingAlpha at 2019-01-31 02:21:58:000
To what should be absolutely no human being's surprise, another amyloid-antibody trial has failed. Roche ([[RHHBY]]) announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. The company is still going on with… read more...
Another Alzheimer's Antibody Fails. There Will Be More
via: SeekingAlpha at 2019-01-31 02:21:58:000
To what should be absolutely no human being's surprise, another amyloid-antibody trial has failed. Roche ([[RHHBY]]) announced today that the Phase III work (two 750-patient trials) on crenezumab after an interim analysis showed a strong chance of futility. The company is still going on with… read more...
Microcaps mostly among midday movers
via: SeekingAlpha at 2019-01-30 12:52:12:000
Gainers: Co-Diagnostics (NASDAQ: CODX ) +114% . China SXT Pharmaceuticals (NASDAQ: SXTC ) +72% . Foresight Autonomous Holdings (NASDAQ: FRSX ) +31% . Horizon Global (NYSE: HZN ) +26% . BIO-key International (NASDAQ: BKYI ) +23% .Eyenovia (NASDAQ: EYEN ) +21% .Dunxin… read more...
TUP and ALGN among premarket losers
via: SeekingAlpha at 2019-01-30 09:12:44:000
AC Immune SA (NASDAQ: ACIU ) -50% after discontinuing Phase III CREAD 1 and 2 studies of Crenezumab. More news on: AC Immune SA, Tupperware Brands Corporation, Trevena, Inc., Stocks on the move, , Read more … read more...
Roche bails on late-stage studies of crenezumab in Alzheimer's
via: SeekingAlpha at 2019-01-30 07:02:26:000
Roche ( OTCQX:RHHBY ) unit Genentech has decided to terminate its Phase 3 clinical trials, CREAD 1 and CREAD 2, evaluating crenezumab in people with early sporadic Alzheimer's disease (AD) after an interim analysis by the Independent Data Monitoring Committee showed that the studies were u… read more...
AC immune announces appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
via: SeekingAlpha at 2019-01-03 07:17:54:000
AC Immune SA ( ACIU ) appointed Dr. Marie Kosco-Vilbois, as Chief Scientific Officer, effective January 3, 2019. More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC immune announces appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
via: SeekingAlpha at 2019-01-03 07:17:54:000
AC Immune SA ( ACIU ) appointed Dr. Marie Kosco-Vilbois, as Chief Scientific Officer, effective January 3, 2019. More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC immune announces appointment of Dr. Marie Kosco-Vilbois as Chief Scientific Officer
via: SeekingAlpha at 2019-01-03 07:17:54:000
AC Immune SA ( ACIU ) appointed Dr. Marie Kosco-Vilbois, as Chief Scientific Officer, effective January 3, 2019. More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune and Wuxi Biologics to establish an exclusive strategic partnership
via: SeekingAlpha at 2018-12-19 08:00:33:000
AC Immune (NASDAQ: ACIU ) and WuXi Biologics ( OTCPK:WXXWY ) announces an exclusive strategic collaboration that covers biologics discovery, development and manufacturing. More news on: AC Immune SA, Wuxi Biologics (Cayman) Inc ADR, Healthcare stocks news, Read more … read more...
AC Immune and Wuxi Biologics to establish an exclusive strategic partnership
via: SeekingAlpha at 2018-12-19 08:00:33:000
AC Immune (NASDAQ: ACIU ) and WuXi Biologics ( OTCPK:WXXWY ) announces an exclusive strategic collaboration that covers biologics discovery, development and manufacturing. More news on: AC Immune SA, Wuxi Biologics (Cayman) Inc ADR, Healthcare stocks news, Read more … read more...
AC Immune and Wuxi Biologics to establish an exclusive strategic partnership
via: SeekingAlpha at 2018-12-19 08:00:33:000
AC Immune (NASDAQ: ACIU ) and WuXi Biologics ( OTCPK:WXXWY ) announces an exclusive strategic collaboration that covers biologics discovery, development and manufacturing. More news on: AC Immune SA, Wuxi Biologics (Cayman) Inc ADR, Healthcare stocks news, Read more … read more...
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership
via: PR Newswire at 2018-12-19 07:16:00:000
AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics AC Immune to gain access to WuXi Biologics' proprie… read more...
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership
via: PR Newswire at 2018-12-19 07:16:00:000
AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics AC Immune to gain access to WuXi Biologics' proprie… read more...
WuXi Biologics and AC Immune to Establish an Exclusive Strategic Partnership
via: PR Newswire at 2018-12-19 07:16:00:000
AC Immune to draw on WuXi Biologics' expertise in manufacturing innovative New Biological Entities against CNS disorders including proprietary WuXiUP continuous manufacturing platform that can significantly reduce cost of biologics AC Immune to gain access to WuXi Biologics' proprie… read more...
Eli Lilly Moving From One End Of The Spectrum To The Other For Alzheimer's Treatment
via: SeekingAlpha at 2018-12-17 08:51:08:000
Recently, Eli Lilly ( LLY ) announced that it had formed a partnership deal for $2 billion to get its hands on an experimental drug for treatment of Alzheimer's disease. This deal marks for a major push for the company to develop a treatment for this neurological disease where treatment op… read more...
Eli Lilly Moving From One End Of The Spectrum To The Other For Alzheimer's Treatment
via: SeekingAlpha at 2018-12-17 08:51:08:000
Recently, Eli Lilly ( LLY ) announced that it had formed a partnership deal for $2 billion to get its hands on an experimental drug for treatment of Alzheimer's disease. This deal marks for a major push for the company to develop a treatment for this neurological disease where treatment op… read more...
Lilly and AC immune signs license and collaboration agreement
via: SeekingAlpha at 2018-12-12 06:46:25:000
Eli Lilly and Company (NYSE: LLY ) and AC Immune (NASDAQ: ACIU ) have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. More news on:… read more...
Lilly and AC immune signs license and collaboration agreement
via: SeekingAlpha at 2018-12-12 06:46:25:000
Eli Lilly and Company (NYSE: LLY ) and AC Immune (NASDAQ: ACIU ) have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. More news on:… read more...
Lilly and AC immune signs license and collaboration agreement
via: SeekingAlpha at 2018-12-12 06:46:25:000
Eli Lilly and Company (NYSE: LLY ) and AC Immune (NASDAQ: ACIU ) have signed a license and collaboration agreement to research and develop tau aggregation inhibitor small molecules for the potential treatment of Alzheimer's disease (AD) and other neurodegenerative diseases. More news on:… read more...
AC Immune and Lilly Announce License and Collaboration Agreement
via: Business Wire at 2018-12-12 06:30:00:000
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimers disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential … read more...
AC Immune and Lilly Announce License and Collaboration Agreement
via: Business Wire at 2018-12-12 06:30:00:000
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimers disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential … read more...
AC Immune and Lilly Announce License and Collaboration Agreement
via: Business Wire at 2018-12-12 06:30:00:000
Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimers disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment of CHF80 million and will be eligible for CHF60 million in potential … read more...
Lilly and AC Immune Announce License and Collaboration Agreement
via: PR Newswire at 2018-12-12 06:00:00:000
INDIANAPOLIS and LAUSANNE, Switzerland , Dec. 12, 2018 /PRNewswire/ -- Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment o… read more...
Lilly and AC Immune Announce License and Collaboration Agreement
via: PR Newswire at 2018-12-12 06:00:00:000
INDIANAPOLIS and LAUSANNE, Switzerland , Dec. 12, 2018 /PRNewswire/ -- Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment o… read more...
Lilly and AC Immune Announce License and Collaboration Agreement
via: PR Newswire at 2018-12-12 06:00:00:000
INDIANAPOLIS and LAUSANNE, Switzerland , Dec. 12, 2018 /PRNewswire/ -- Multi-year agreement focuses on Morphomer tau aggregation inhibitors, for the potential treatment of Alzheimer's disease and other neurodegenerative diseases. AC Immune to receive an initial upfront payment o… read more...
Week 50 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-12-09 13:12:53:000
2018 YTD Chart: +38.68% The benchmark S&P 500 index continues into negative territory for 2018 with over 5% declines this past week. The Momentum Gauges The Momentum Gauge signals continue to maintain higher levels of negative momentum than positive momentum since week 39 (last we… read more...
Week 50 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-12-09 13:12:53:000
2018 YTD Chart: +38.68% The benchmark S&P 500 index continues into negative territory for 2018 with over 5% declines this past week. The Momentum Gauges The Momentum Gauge signals continue to maintain higher levels of negative momentum than positive momentum since week 39 (last we… read more...
Leerink sees 34% upside in Allergan in premarket analyst action
via: SeekingAlpha at 2018-11-13 08:20:25:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Leerink sees 34% upside in Allergan in premarket analyst action
via: SeekingAlpha at 2018-11-13 08:20:25:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
Leerink sees 34% upside in Allergan in premarket analyst action
via: SeekingAlpha at 2018-11-13 08:20:25:000
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Market Perform rating at Leerink Partners. More news on: ACADIA Pharmaceuticals Inc., AC Immune SA, Adamas Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the move, , Read more … read more...
AC Immune reports Q3 results
via: SeekingAlpha at 2018-11-13 05:43:41:000
AC Immune (NASDAQ: ACIU ): Q3 Non-GAAP EPS of -CHF0.18; GAAP EPS of -CHF0.21. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q3 results
via: SeekingAlpha at 2018-11-13 05:43:41:000
AC Immune (NASDAQ: ACIU ): Q3 Non-GAAP EPS of -CHF0.18; GAAP EPS of -CHF0.21. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q3 results
via: SeekingAlpha at 2018-11-13 05:43:41:000
AC Immune (NASDAQ: ACIU ): Q3 Non-GAAP EPS of -CHF0.18; GAAP EPS of -CHF0.21. More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune partner Life Molecular Imaging presents clinical study results for Tau PET-Tracer 18F-PI-2620
via: SeekingAlpha at 2018-10-29 08:00:17:000
AC Immune SA (NASDAQ: ACIU ) announces that its partner Life Molecular Imaging (LMI) has presented new clinical study results for 18F-PI-2620, a tau PET-tracer, allowing further extension of tau PET investigations with this compound in therapeutic clinical trials. More news on: AC Immune… read more...
AC Immune partner Life Molecular Imaging presents clinical study results for Tau PET-Tracer 18F-PI-2620
via: SeekingAlpha at 2018-10-29 08:00:17:000
AC Immune SA (NASDAQ: ACIU ) announces that its partner Life Molecular Imaging (LMI) has presented new clinical study results for 18F-PI-2620, a tau PET-tracer, allowing further extension of tau PET investigations with this compound in therapeutic clinical trials. More news on: AC Immune… read more...
AC Immune partner Life Molecular Imaging presents clinical study results for Tau PET-Tracer 18F-PI-2620
via: SeekingAlpha at 2018-10-29 08:00:17:000
AC Immune SA (NASDAQ: ACIU ) announces that its partner Life Molecular Imaging (LMI) has presented new clinical study results for 18F-PI-2620, a tau PET-tracer, allowing further extension of tau PET investigations with this compound in therapeutic clinical trials. More news on: AC Immune… read more...
Week 43 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-10-22 08:11:58:000
2018 YTD Chart: +49.00% Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 43: The Momentum Gauge conditions continue to worsen over the past several weeks since Week 39. The positive momentum gauge is now down to 7 from a value of 65 at the end of We… read more...
Week 43 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-10-22 08:11:58:000
2018 YTD Chart: +49.00% Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 43: The Momentum Gauge conditions continue to worsen over the past several weeks since Week 39. The positive momentum gauge is now down to 7 from a value of 65 at the end of We… read more...
Week 43 Breakout Forecast: Short-Term Picks To Give You An Edge
via: SeekingAlpha at 2018-10-22 08:11:58:000
2018 YTD Chart: +49.00% Cumulative return with 1-Week holding period. Breakout Forecast Selections for Week 43: The Momentum Gauge conditions continue to worsen over the past several weeks since Week 39. The positive momentum gauge is now down to 7 from a value of 65 at the end of We… read more...
AC Immune holder files to sell 18M shares
via: SeekingAlpha at 2018-08-24 19:09:27:000
Swiss biopharmaceutical firm AC Immune (NASDAQ: ACIU ) has registered just over 18M shares to be offered by a selling shareholder . More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune holder files to sell 18M shares
via: SeekingAlpha at 2018-08-24 19:09:27:000
Swiss biopharmaceutical firm AC Immune (NASDAQ: ACIU ) has registered just over 18M shares to be offered by a selling shareholder . More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune holder files to sell 18M shares
via: SeekingAlpha at 2018-08-24 19:09:27:000
Swiss biopharmaceutical firm AC Immune (NASDAQ: ACIU ) has registered just over 18M shares to be offered by a selling shareholder . More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune holder files to sell 18M shares
via: SeekingAlpha at 2018-08-24 19:09:27:000
Swiss biopharmaceutical firm AC Immune (NASDAQ: ACIU ) has registered just over 18M shares to be offered by a selling shareholder . More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune holder files to sell 18M shares
via: SeekingAlpha at 2018-08-24 19:09:27:000
Swiss biopharmaceutical firm AC Immune (NASDAQ: ACIU ) has registered just over 18M shares to be offered by a selling shareholder . More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
Your Daily Pharma Scoop: AC Immune Progresses, Keytruda's Further Approval, Novo Nordisk Phase 3 Positive
via: SeekingAlpha at 2018-08-22 11:33:17:000
Stocks in News: ACIU, MRK AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1% Discussion : AC Immunes ( ACIU ) anti-Abeta vaccine development program recently reached two clinical milestones. To confirm the positive results of an earlier Phase 1 study of its can… read more...
Your Daily Pharma Scoop: AC Immune Progresses, Keytruda's Further Approval, Novo Nordisk Phase 3 Positive
via: SeekingAlpha at 2018-08-22 11:33:17:000
Stocks in News: ACIU, MRK AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1% Discussion : AC Immunes ( ACIU ) anti-Abeta vaccine development program recently reached two clinical milestones. To confirm the positive results of an earlier Phase 1 study of its can… read more...
Your Daily Pharma Scoop: AC Immune Progresses, Keytruda's Further Approval, Novo Nordisk Phase 3 Positive
via: SeekingAlpha at 2018-08-22 11:33:17:000
Stocks in News: ACIU, MRK AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1% Discussion : AC Immunes ( ACIU ) anti-Abeta vaccine development program recently reached two clinical milestones. To confirm the positive results of an earlier Phase 1 study of its can… read more...
AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1%
via: SeekingAlpha at 2018-08-20 09:58:50:000
AC Immune SA ( ACIU +1.1% ) announces two clinical milestone related to anti-Abeta vaccine candidate ACI-24. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more … read more...
AC Immune advancing anti-Abeta vaccine ACI-24; shares up 1%
via: SeekingAlpha at 2018-08-20 09:58:50:000
AC Immune SA ( ACIU +1.1% ) announces two clinical milestone related to anti-Abeta vaccine candidate ACI-24. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more … read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2018-08-08 04:57:55:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.19 Revenue of CHF2M (+150.0% Y/Y) Press Release More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2018-08-08 04:57:55:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.19 Revenue of CHF2M (+150.0% Y/Y) Press Release More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2018-08-08 04:57:55:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.19 Revenue of CHF2M (+150.0% Y/Y) Press Release More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, read more...
Forensic Stock Selections For August - First Year Portfolio +96.80%
via: SeekingAlpha at 2018-08-01 01:29:07:000
Forensic Value Stock Selections The following stock selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year-over-year operational performance measures. The combination of all three bankruptcy and financial irregularity algorit… read more...
Forensic Stock Selections For August - First Year Portfolio +96.80%
via: SeekingAlpha at 2018-08-01 01:29:07:000
Forensic Value Stock Selections The following stock selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year-over-year operational performance measures. The combination of all three bankruptcy and financial irregularity algorit… read more...
Forensic Stock Selections For August - First Year Portfolio +96.80%
via: SeekingAlpha at 2018-08-01 01:29:07:000
Forensic Value Stock Selections The following stock selections using three forensic algorithms from the financial literature rely exclusively on fundamental data and year-over-year operational performance measures. The combination of all three bankruptcy and financial irregularity algorit… read more...
Midday Gainers / Losers (07/26/2018)
via: SeekingAlpha at 2018-07-26 12:40:18:000
Gainers: BSPM +105% . SVU +64% . BPI +50% . PCMI +26% . JBT +22% . AWX +20% . ANIK +18% . MTSL +15% . ADMA +17% . KODK +17% . More news on: Biostar Pharmaceutic, SUPERVALU Inc., Bridgepoint Education, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/26/2018)
via: SeekingAlpha at 2018-07-26 12:40:18:000
Gainers: BSPM +105% . SVU +64% . BPI +50% . PCMI +26% . JBT +22% . AWX +20% . ANIK +18% . MTSL +15% . ADMA +17% . KODK +17% . More news on: Biostar Pharmaceutic, SUPERVALU Inc., Bridgepoint Education, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/26/2018)
via: SeekingAlpha at 2018-07-26 12:40:18:000
Gainers: BSPM +105% . SVU +64% . BPI +50% . PCMI +26% . JBT +22% . AWX +20% . ANIK +18% . MTSL +15% . ADMA +17% . KODK +17% . More news on: Biostar Pharmaceutic, SUPERVALU Inc., Bridgepoint Education, Inc., Stocks on the move, , Read more … read more...
Biogen slump pressures other biotechs
via: SeekingAlpha at 2018-07-26 10:32:00:000
Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...
Biogen slump pressures other biotechs
via: SeekingAlpha at 2018-07-26 10:32:00:000
Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...
Biogen slump pressures other biotechs
via: SeekingAlpha at 2018-07-26 10:32:00:000
Biogen's ( BIIB -8.9% ) post-BAN2401 data-stoked drop appears to be affecting some of the other Alzheimer's players. More news on: Biogen Inc., SPDR Biotech ETF, Eisai Co., Ltd. ADR, Healthcare stocks news, Stocks on the move, News on ETFs, Read more … read more...
AC Immune -12% as Biogen's Alzheimer's data fails to impress
via: SeekingAlpha at 2018-07-25 19:05:59:000
AC Immune (NASDAQ: ACIU ) -11.9% after-hours after an experimental Alzheimers disease drug from Biogen (NASDAQ: BIIB ) and Eisai ( OTCPK:ESALY ) failed to elicit "shock and awe" in presentation data at a medical meeting. More news on: AC Immune SA, Biogen Inc., Eisai Co., Ltd. … read more...
Recognize These Week 29 Winners? Top 10 Stocks Across Multiple Financial Algorithms
via: SeekingAlpha at 2018-07-22 05:59:59:000
Week 29 Summary Results It is not the amount of knowledge that makes a brain. It is not even the distribution of knowledge. It is the interconnectedness. James Gleick, The Information: A History, a Theory, a Flood * Table excludes weekly momentum portfolios m… read more...
Recognize These Week 29 Winners? Top 10 Stocks Across Multiple Financial Algorithms
via: SeekingAlpha at 2018-07-22 05:59:59:000
Week 29 Summary Results It is not the amount of knowledge that makes a brain. It is not even the distribution of knowledge. It is the interconnectedness. James Gleick, The Information: A History, a Theory, a Flood * Table excludes weekly momentum portfolios m… read more...
Recognize These Week 29 Winners? Top 10 Stocks Across Multiple Financial Algorithms
via: SeekingAlpha at 2018-07-22 05:59:59:000
Week 29 Summary Results It is not the amount of knowledge that makes a brain. It is not even the distribution of knowledge. It is the interconnectedness. James Gleick, The Information: A History, a Theory, a Flood * Table excludes weekly momentum portfolios m… read more...
Midday Gainers / Losers (07/19/2018)
via: SeekingAlpha at 2018-07-19 12:35:17:000
Gainers: SMIT +29% . TCP +27% . MTSL +27% . DM +26% . ACIU +18% . MDXG +15% . IMTE +16% . IIIN +13% . DWCH +12% . TTS +12% . More news on: Schmitt Industries, Inc., TC PipeLines, LP, MER Telemanagement Solutions Ltd., Stocks on the move, , Read more …... read more...
Midday Gainers / Losers (07/19/2018)
via: SeekingAlpha at 2018-07-19 12:35:17:000
Gainers: SMIT +29% . TCP +27% . MTSL +27% . DM +26% . ACIU +18% . MDXG +15% . IMTE +16% . IIIN +13% . DWCH +12% . TTS +12% . More news on: Schmitt Industries, Inc., TC PipeLines, LP, MER Telemanagement Solutions Ltd., Stocks on the move, , Read more …... read more...
Midday Gainers / Losers (07/19/2018)
via: SeekingAlpha at 2018-07-19 12:35:17:000
Gainers: SMIT +29% . TCP +27% . MTSL +27% . DM +26% . ACIU +18% . MDXG +15% . IMTE +16% . IIIN +13% . DWCH +12% . TTS +12% . More news on: Schmitt Industries, Inc., TC PipeLines, LP, MER Telemanagement Solutions Ltd., Stocks on the move, , Read more …... read more...
Premarket Gainers as of 9:05 am (07/19/2018)
via: SeekingAlpha at 2018-07-19 09:13:36:000
SMIT +40% on Q4 result . More news on: Schmitt Industries, Inc., Dominion Midstream Partners LP, Arcadia Biosciences, Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (07/19/2018)
via: SeekingAlpha at 2018-07-19 09:13:36:000
SMIT +40% on Q4 result . More news on: Schmitt Industries, Inc., Dominion Midstream Partners LP, Arcadia Biosciences, Stocks on the move, Read more … read more...
Premarket Gainers as of 9:05 am (07/19/2018)
via: SeekingAlpha at 2018-07-19 09:13:36:000
SMIT +40% on Q4 result . More news on: Schmitt Industries, Inc., Dominion Midstream Partners LP, Arcadia Biosciences, Stocks on the move, Read more … read more...
AC Immune prices its 10M equity offering, shares up 1.4% premarket
via: SeekingAlpha at 2018-07-19 07:55:45:000
AC Immune SA (NASDAQ: ACIU ) has priced 10M new common shares offering at $11.75 per share, for gross proceeds of ~$86.8M. More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune prices its 10M equity offering, shares up 1.4% premarket
via: SeekingAlpha at 2018-07-19 07:55:45:000
AC Immune SA (NASDAQ: ACIU ) has priced 10M new common shares offering at $11.75 per share, for gross proceeds of ~$86.8M. More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune prices its 10M equity offering, shares up 1.4% premarket
via: SeekingAlpha at 2018-07-19 07:55:45:000
AC Immune SA (NASDAQ: ACIU ) has priced 10M new common shares offering at $11.75 per share, for gross proceeds of ~$86.8M. More news on: AC Immune SA, Healthcare stocks news, Read more … read more...
AC Immune readies 8.5M-share rights offering
via: SeekingAlpha at 2018-07-17 16:21:04:000
AC Immune SA (NASDAQ: ACIU ) announces plans for a subscription rights offering to current shareholders for up to 8.5M common shares. Concurrently, it will execute a public offering of shares not subscribed by shareholders. More news on: AC Immune SA, Healthcare stocks news, Read mor… read more...
AC Immune readies 8.5M-share rights offering
via: SeekingAlpha at 2018-07-17 16:21:04:000
AC Immune SA (NASDAQ: ACIU ) announces plans for a subscription rights offering to current shareholders for up to 8.5M common shares. Concurrently, it will execute a public offering of shares not subscribed by shareholders. More news on: AC Immune SA, Healthcare stocks news, Read mor… read more...
Midday Gainers / Losers (07/11/2018)
via: SeekingAlpha at 2018-07-11 12:42:53:000
Gainers: MDGS +79% . MYOS +42% . BIOC +28% . ACHV +24% . TKAT +18% . ACIU +15% . MYGN +15% . WMLP +14% . MTSL +14% . INTX +13% . More news on: Medigus Ltd, MYOS RENS Technology, Biocept, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/11/2018)
via: SeekingAlpha at 2018-07-11 12:42:53:000
Gainers: MDGS +79% . MYOS +42% . BIOC +28% . ACHV +24% . TKAT +18% . ACIU +15% . MYGN +15% . WMLP +14% . MTSL +14% . INTX +13% . More news on: Medigus Ltd, MYOS RENS Technology, Biocept, Inc., Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/11/2018)
via: SeekingAlpha at 2018-07-11 12:42:53:000
Gainers: MDGS +79% . MYOS +42% . BIOC +28% . ACHV +24% . TKAT +18% . ACIU +15% . MYGN +15% . WMLP +14% . MTSL +14% . INTX +13% . More news on: Medigus Ltd, MYOS RENS Technology, Biocept, Inc., Stocks on the move, , Read more … read more...
Your Daily Pharma Scoop: Biogen Rallies, AC Immune Goes Up, Not Everyone On Board With Biogen
via: SeekingAlpha at 2018-07-08 02:53:35:000
Stocks in News: Biogen rallies after Alzheimer's drug succeeds in trial News of final analysis of a Phase 2 clinical trial of BAN2401, an Alzheimers drug developed by Biogen ( BIIB ) with Japanese partner Eisai pushed the stock initially by 6.4%. However, it is now close to 20%… read more...
Your Daily Pharma Scoop: Biogen Rallies, AC Immune Goes Up, Not Everyone On Board With Biogen
via: SeekingAlpha at 2018-07-08 02:53:35:000
Stocks in News: Biogen rallies after Alzheimer's drug succeeds in trial News of final analysis of a Phase 2 clinical trial of BAN2401, an Alzheimers drug developed by Biogen ( BIIB ) with Japanese partner Eisai pushed the stock initially by 6.4%. However, it is now close to 20%… read more...
Your Daily Pharma Scoop: Biogen Rallies, AC Immune Goes Up, Not Everyone On Board With Biogen
via: SeekingAlpha at 2018-07-08 02:53:35:000
Stocks in News: Biogen rallies after Alzheimer's drug succeeds in trial News of final analysis of a Phase 2 clinical trial of BAN2401, an Alzheimers drug developed by Biogen ( BIIB ) with Japanese partner Eisai pushed the stock initially by 6.4%. However, it is now close to 20%… read more...
Midday Gainers / Losers (07/06/2018)
via: SeekingAlpha at 2018-07-06 12:38:11:000
Gainers: XBIO +33% . ACIU +33% . OTCPK:LFIN +29% . TAIT +24% . ARQL +19% . MNOV +18% . MOTS +17% . BIIB +16% . ATOS +13% . LFVN +12% . More news on: Xenetic Biosciences, Inc., AC Immune SA, LongFin Corp.A, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (07/06/2018)
via: SeekingAlpha at 2018-07-06 12:38:11:000
Gainers: XBIO +33% . ACIU +33% . OTCPK:LFIN +29% . TAIT +24% . ARQL +19% . MNOV +18% . MOTS +17% . BIIB +16% . ATOS +13% . LFVN +12% . More news on: Xenetic Biosciences, Inc., AC Immune SA, LongFin Corp.A, Stocks on the move, , Read more … read more...
Alzheimer's players in the green on Biogen news
via: SeekingAlpha at 2018-07-06 10:12:33:000
Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Alzheimer's players in the green on Biogen news
via: SeekingAlpha at 2018-07-06 10:12:33:000
Most players in the Alzheimer's disease space are in the green after Biogen announced positive mid-stage data on BAN2401. More news on: vTv Therapeutics, Tonix Pharmaceuticals Holding Corp., ACADIA Pharmaceuticals Inc., Healthcare stocks news, Stocks on the move, Read more … read more...
Biogen bullishness spreads to AC Immune, up 32%
via: SeekingAlpha at 2018-07-06 10:06:48:000
Thinly traded AC Immune ( ACIU +32.4% ) is up a 16x surge in volume in apparent concert with Biogen's ( BIIB +17.9% ) rally related to positive Phase 2 data on early Alzheimer's candidate BAN2401, a humanized anti-amyloid beta protofil monoclonal antibody. More news on: AC Immune SA, B… read more...
Biogen bullishness spreads to AC Immune, up 32%
via: SeekingAlpha at 2018-07-06 10:06:48:000
Thinly traded AC Immune ( ACIU +32.4% ) is up a 16x surge in volume in apparent concert with Biogen's ( BIIB +17.9% ) rally related to positive Phase 2 data on early Alzheimer's candidate BAN2401, a humanized anti-amyloid beta protofil monoclonal antibody. More news on: AC Immune SA, B… read more...
Midday Gainers / Losers (06/05/2018)
via: SeekingAlpha at 2018-06-05 12:35:14:000
Gainers: CODX +41% . NDRA +28% . SDT +32% . SNES +25% . CLDC +19% . ABEO +15% . NX +16% . ANFI +15% . ACIU +15% . SMAR +15% . More news on: Co-Diagnostics, Endra Life Sciences Inc, SandRidge Mississippian Trust I, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/05/2018)
via: SeekingAlpha at 2018-06-05 12:35:14:000
Gainers: CODX +41% . NDRA +28% . SDT +32% . SNES +25% . CLDC +19% . ABEO +15% . NX +16% . ANFI +15% . ACIU +15% . SMAR +15% . More news on: Co-Diagnostics, Endra Life Sciences Inc, SandRidge Mississippian Trust I, Stocks on the move, , Read more … read more...
Midday Gainers / Losers (06/05/2018)
via: SeekingAlpha at 2018-06-05 12:35:14:000
Gainers: CODX +41% . NDRA +28% . SDT +32% . SNES +25% . CLDC +19% . ABEO +15% . NX +16% . ANFI +15% . ACIU +15% . SMAR +15% . More news on: Co-Diagnostics, Endra Life Sciences Inc, SandRidge Mississippian Trust I, Stocks on the move, , Read more … read more...
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
via: SeekingAlpha at 2018-05-14 12:27:31:000
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...
Oryzon Genomics commences mid-stage study of Alzheimer's candidate
via: SeekingAlpha at 2018-05-14 12:27:31:000
Spanish biotech Oryzon Genomics announces that enrollment is underway in a Phase 2b clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: vTv Therapeutics, Biogen Inc., Tonix Pharmaceuticals Holding Corp., Healthcare stocks news, … read more...
AC Immune reports Q1 results
via: SeekingAlpha at 2018-05-02 04:04:48:000
AC Immune (NASDAQ: ACIU ): Q1 EPS of -CHF0.19 Revenue of CHF1.5M (-25.0% Y/Y) Press Release More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, read more...
AC Immune reports Q1 results
via: SeekingAlpha at 2018-05-02 04:04:48:000
AC Immune (NASDAQ: ACIU ): Q1 EPS of -CHF0.19 Revenue of CHF1.5M (-25.0% Y/Y) Press Release More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, read more...
AC Immune (ACIU) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
via: SeekingAlpha at 2018-04-10 12:17:52:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Presents At H. C. Wainwright Global Life Sciences Conference - Slideshow
via: SeekingAlpha at 2018-04-10 12:17:52:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study
via: SeekingAlpha at 2018-04-06 11:18:40:000
A nalysis focus: Conatus Conatus (NASDAQ: CNAT ) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNATs lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor … read more...
Your Daily Pharma Scoop: Conatus Setback, Applied DNA Signs Agreement, Evolus Announces Results From Late-Stage Study
via: SeekingAlpha at 2018-04-06 11:18:40:000
A nalysis focus: Conatus Conatus (NASDAQ: CNAT ) shares tumbled after the company announced top-line results from a phase 2b POLT-HCV-SVR clinical study. The phase 2b study was evaluating CNATs lead product candidate emricasan, a first-in-class pan-caspase protease inhibitor … read more...
AC immune selects Tau candidates for Alzheimer's disease
via: SeekingAlpha at 2018-04-05 08:26:31:000
AC Immune SA (NASDAQ: ACIU ) announces that several Tau Morphomer candidates have demonstrated target-specific reduction of pathological Tau and cognitive and functional improvement in Alzheimer's disease in preclinical testing. More news on: AC Immune SA, Healthcare stocks news, Rea… read more...
AC immune selects Tau candidates for Alzheimer's disease
via: SeekingAlpha at 2018-04-05 08:26:31:000
AC Immune SA (NASDAQ: ACIU ) announces that several Tau Morphomer candidates have demonstrated target-specific reduction of pathological Tau and cognitive and functional improvement in Alzheimer's disease in preclinical testing. More news on: AC Immune SA, Healthcare stocks news, Rea… read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-04-05 07:21:27:000
AC Immune (NASDAQ: ACIU ) initiated with Buy rating with an $18 (67% upside) price target at H.C. Wainwright. More news on: AC Immune SA, Merck & Co Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...
Premarket analyst action - healthcare
via: SeekingAlpha at 2018-04-05 07:21:27:000
AC Immune (NASDAQ: ACIU ) initiated with Buy rating with an $18 (67% upside) price target at H.C. Wainwright. More news on: AC Immune SA, Merck & Co Inc., Pfizer Inc., Healthcare stocks news, Read more … read more...
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
via: SeekingAlpha at 2018-04-04 11:14:00:000
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news… read more...
Oryzon Genomics on go with mid-stage study of Alzheimer's candidate ORY-2001
via: SeekingAlpha at 2018-04-04 11:14:00:000
Madrid, Spain-based Oryzon Genomics announces that it has received regulatory sign-off for a Phase 2a clinical trial assessing ORY-2001 in patients with mild-to-moderate Alzheimer's disease (AD). More news on: Alzheon, Denali Therapeutics, Inc., Wave Life Sciences, Healthcare stocks news… read more...
AC Immune reports FY results
via: SeekingAlpha at 2018-03-20 05:29:06:000
AC Immune (NASDAQ: ACIU ): FY EPS of -CHF0.36 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports FY results
via: SeekingAlpha at 2018-03-20 05:29:06:000
AC Immune (NASDAQ: ACIU ): FY EPS of -CHF0.36 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune to launch first in-human study of PET tracer for Parkinson's in H2
via: SeekingAlpha at 2018-03-15 11:24:33:000
AC Immune ( ACIU -0.4% ) announces that it plans to initiate a first in-human study of its investigational PET imaging agent for Parkinson's disease (PD). The company says the agent is highly selective for alpha-synuclein aggregates, an established drug target for the disorder. The trace… read more...
AC Immune to launch first in-human study of PET tracer for Parkinson's in H2
via: SeekingAlpha at 2018-03-15 11:24:33:000
AC Immune ( ACIU -0.4% ) announces that it plans to initiate a first in-human study of its investigational PET imaging agent for Parkinson's disease (PD). The company says the agent is highly selective for alpha-synuclein aggregates, an established drug target for the disorder. The trace… read more...
Forensic Analysis Value Stock Selections - December
via: SeekingAlpha at 2017-12-01 18:39:20:000
Forensic Value Portfolio YTD Returns - November End The adverse scoring forensic portfolios (above) with the most adverse scores across all three of the academic forensic models continue to significantly outperform both the market as well as the portfolios with the highest positive forensic … read more...
Forensic Analysis Value Stock Selections - December
via: SeekingAlpha at 2017-12-01 18:39:20:000
Forensic Value Portfolio YTD Returns - November End The adverse scoring forensic portfolios (above) with the most adverse scores across all three of the academic forensic models continue to significantly outperform both the market as well as the portfolios with the highest positive forensic … read more...
Forensic Analysis Value Stock Selections - December
via: SeekingAlpha at 2017-12-01 18:39:20:000
Forensic Value Portfolio YTD Returns - November End The adverse scoring forensic portfolios (above) with the most adverse scores across all three of the academic forensic models continue to significantly outperform both the market as well as the portfolios with the highest positive forensic … read more...
Forensic Analysis Value Stock Selections - December
via: SeekingAlpha at 2017-12-01 18:39:20:000
Forensic Value Portfolio YTD Returns - November End The adverse scoring forensic portfolios (above) with the most adverse scores across all three of the academic forensic models continue to significantly outperform both the market as well as the portfolios with the highest positive forensic … read more...
Forensic Analysis Value Stock Selections - December
via: SeekingAlpha at 2017-12-01 18:39:20:000
Forensic Value Portfolio YTD Returns - November End The adverse scoring forensic portfolios (above) with the most adverse scores across all three of the academic forensic models continue to significantly outperform both the market as well as the portfolios with the highest positive forensic … read more...
AC Immune (ACIU) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-11-17 13:02:15:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-11-17 13:02:15:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-11-17 13:02:15:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-11-17 13:02:15:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Presents At Jefferies 2017 London Healthcare Conference - Slideshow
via: SeekingAlpha at 2017-11-17 13:02:15:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune misses by $0.03
via: SeekingAlpha at 2017-11-13 06:52:05:000
AC Immune (NASDAQ: ACIU ): Q3 EPS of -$0.16 misses by $0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune misses by $0.03
via: SeekingAlpha at 2017-11-13 06:52:05:000
AC Immune (NASDAQ: ACIU ): Q3 EPS of -$0.16 misses by $0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune misses by $0.03
via: SeekingAlpha at 2017-11-13 06:52:05:000
AC Immune (NASDAQ: ACIU ): Q3 EPS of -$0.16 misses by $0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune misses by $0.03
via: SeekingAlpha at 2017-11-13 06:52:05:000
AC Immune (NASDAQ: ACIU ): Q3 EPS of -$0.16 misses by $0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune misses by $0.03
via: SeekingAlpha at 2017-11-13 06:52:05:000
AC Immune (NASDAQ: ACIU ): Q3 EPS of -$0.16 misses by $0.03 . More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune discovers two new antibodies targeted to neurodegenerative diseases like Alzheimer's; shares ahead 4%
via: SeekingAlpha at 2017-08-22 11:05:46:000
Thinly traded micro cap AC Immune SA ( ACIU +3.5% ) heads north on light volume in response to its announcement that it has discovered two new antibodies using its proprietary SupraAntigen platform. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more …. read more...
AC Immune discovers two new antibodies targeted to neurodegenerative diseases like Alzheimer's; shares ahead 4%
via: SeekingAlpha at 2017-08-22 11:05:46:000
Thinly traded micro cap AC Immune SA ( ACIU +3.5% ) heads north on light volume in response to its announcement that it has discovered two new antibodies using its proprietary SupraAntigen platform. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more …. read more...
AC Immune discovers two new antibodies targeted to neurodegenerative diseases like Alzheimer's; shares ahead 4%
via: SeekingAlpha at 2017-08-22 11:05:46:000
Thinly traded micro cap AC Immune SA ( ACIU +3.5% ) heads north on light volume in response to its announcement that it has discovered two new antibodies using its proprietary SupraAntigen platform. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more …. read more...
AC Immune discovers two new antibodies targeted to neurodegenerative diseases like Alzheimer's; shares ahead 4%
via: SeekingAlpha at 2017-08-22 11:05:46:000
Thinly traded micro cap AC Immune SA ( ACIU +3.5% ) heads north on light volume in response to its announcement that it has discovered two new antibodies using its proprietary SupraAntigen platform. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more …. read more...
AC Immune discovers two new antibodies targeted to neurodegenerative diseases like Alzheimer's; shares ahead 4%
via: SeekingAlpha at 2017-08-22 11:05:46:000
Thinly traded micro cap AC Immune SA ( ACIU +3.5% ) heads north on light volume in response to its announcement that it has discovered two new antibodies using its proprietary SupraAntigen platform. More news on: AC Immune SA, Healthcare stocks news, Stocks on the move, Read more …. read more...
Now Is The Perfect Time To Diversify Internationally
via: SeekingAlpha at 2017-08-18 00:57:09:000
Investment Thesis While US markets are expensive by most metrics, international markets are fairly valued to undervalued. This increases the odds that international markets will outperform the US over the next ten years. Many investors are underexposed to international equities and should in… read more...
Now Is The Perfect Time To Diversify Internationally
via: SeekingAlpha at 2017-08-18 00:57:09:000
Investment Thesis While US markets are expensive by most metrics, international markets are fairly valued to undervalued. This increases the odds that international markets will outperform the US over the next ten years. Many investors are underexposed to international equities and should in… read more...
Now Is The Perfect Time To Diversify Internationally
via: SeekingAlpha at 2017-08-18 00:57:09:000
Investment Thesis While US markets are expensive by most metrics, international markets are fairly valued to undervalued. This increases the odds that international markets will outperform the US over the next ten years. Many investors are underexposed to international equities and should in… read more...
Now Is The Perfect Time To Diversify Internationally
via: SeekingAlpha at 2017-08-18 00:57:09:000
Investment Thesis While US markets are expensive by most metrics, international markets are fairly valued to undervalued. This increases the odds that international markets will outperform the US over the next ten years. Many investors are underexposed to international equities and should in… read more...
Now Is The Perfect Time To Diversify Internationally
via: SeekingAlpha at 2017-08-18 00:57:09:000
Investment Thesis While US markets are expensive by most metrics, international markets are fairly valued to undervalued. This increases the odds that international markets will outperform the US over the next ten years. Many investors are underexposed to international equities and should in… read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2017-08-09 06:48:52:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.14 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2017-08-09 06:48:52:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.14 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2017-08-09 06:48:52:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.14 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2017-08-09 06:48:52:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.14 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
AC Immune reports Q2 results
via: SeekingAlpha at 2017-08-09 06:48:52:000
AC Immune (NASDAQ: ACIU ): Q2 EPS of -CHF0.14 More news on: AC Immune SA, Earnings news and commentary, Healthcare stocks news, Read more … read more...
Value Investment Stock Selections Using Forensic Analysis - August
via: SeekingAlpha at 2017-08-04 11:56:06:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using pub… read more...
Value Investment Stock Selections Using Forensic Analysis - August
via: SeekingAlpha at 2017-08-04 11:56:06:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using pub… read more...
Value Investment Stock Selections Using Forensic Analysis - August
via: SeekingAlpha at 2017-08-04 11:56:06:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using pub… read more...
Value Investment Stock Selections Using Forensic Analysis - August
via: SeekingAlpha at 2017-08-04 11:56:06:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using pub… read more...
Value Investment Stock Selections Using Forensic Analysis - August
via: SeekingAlpha at 2017-08-04 11:56:06:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using pub… read more...
Value Investment Stock Selections Using Forensic Analysis - July
via: SeekingAlpha at 2017-07-24 11:25:59:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using p… read more...
Value Investment Stock Selections Using Forensic Analysis - July
via: SeekingAlpha at 2017-07-24 11:25:59:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using p… read more...
Value Investment Stock Selections Using Forensic Analysis - July
via: SeekingAlpha at 2017-07-24 11:25:59:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using p… read more...
Value Investment Stock Selections Using Forensic Analysis - July
via: SeekingAlpha at 2017-07-24 11:25:59:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using p… read more...
Value Investment Stock Selections Using Forensic Analysis - July
via: SeekingAlpha at 2017-07-24 11:25:59:000
Intro The purpose of this monthly article is to provide investors with additional tools to evaluate financial irregularities according to three different detection models from academic research. It is my hope that this contribution toward improving due diligence in the market place using p… read more...
AC Immune: A Compelling Speculative Investment
via: SeekingAlpha at 2017-07-11 17:01:41:000
Investment Thesis AC Immune (NASDAQ: ACIU ) is trading well below its IPO price, with expectations for its leading candidate diminished due to recent failures by other drug companies. AC Immune is in a strong financial position, and their leading candidate still holds promise. The market … read more...
AC Immune: A Compelling Speculative Investment
via: SeekingAlpha at 2017-07-11 17:01:41:000
Investment Thesis AC Immune (NASDAQ: ACIU ) is trading well below its IPO price, with expectations for its leading candidate diminished due to recent failures by other drug companies. AC Immune is in a strong financial position, and their leading candidate still holds promise. The market … read more...
AC Immune: A Compelling Speculative Investment
via: SeekingAlpha at 2017-07-11 17:01:41:000
Investment Thesis AC Immune (NASDAQ: ACIU ) is trading well below its IPO price, with expectations for its leading candidate diminished due to recent failures by other drug companies. AC Immune is in a strong financial position, and their leading candidate still holds promise. The market … read more...
AC Immune: A Compelling Speculative Investment
via: SeekingAlpha at 2017-07-11 17:01:41:000
Investment Thesis AC Immune (NASDAQ: ACIU ) is trading well below its IPO price, with expectations for its leading candidate diminished due to recent failures by other drug companies. AC Immune is in a strong financial position, and their leading candidate still holds promise. The market … read more...
AC Immune: A Compelling Speculative Investment
via: SeekingAlpha at 2017-07-11 17:01:41:000
Investment Thesis AC Immune (NASDAQ: ACIU ) is trading well below its IPO price, with expectations for its leading candidate diminished due to recent failures by other drug companies. AC Immune is in a strong financial position, and their leading candidate still holds promise. The market … read more...
AC Immune (ACIU) Investor Presentation - Slideshow
via: SeekingAlpha at 2017-06-28 07:55:06:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Investor Presentation - Slideshow
via: SeekingAlpha at 2017-06-28 07:55:06:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Investor Presentation - Slideshow
via: SeekingAlpha at 2017-06-28 07:55:06:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Investor Presentation - Slideshow
via: SeekingAlpha at 2017-06-28 07:55:06:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
AC Immune (ACIU) Investor Presentation - Slideshow
via: SeekingAlpha at 2017-06-28 07:55:06:000
The following slide deck was published by AC Immune SA in conjunction with this Read more … read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|